Medical

Mucosis has initiated a Phase 1 study of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. In January 2016, Mucosis announced that it had received a €3.7 million grant from the Wellcome… Read more . . .

Spyryx Biosciences has presented data from preclinical studies of its SPX-101 inhaled SPLUNC1-derived peptide showing that SPX-101 improves mucus clearance and survival in animal models of cystic fibrosis and demonstrated no toxicity. The data were… Read more . . .

Arch Biopartners has announced that Dr. Ralph Panos of the Cincinnati Veterans Affairs Medical Center (CVAMC) will prepare a protocol for human trials of the company’s AB569 inhaled bactericide and will subsequently prepare an application… Read more . . .

Upsher-Smith Laboratories has presented data from a Phase 1 study of its USL261 midazolam nasal spray in children with epilepsy demonstrating that the median Tmax for 1.25 mg, 2.5 mg and 5 mg single doses… Read more . . .

Windtree Therapeutics has announced that a lung deposition study in cynomolgus macaques showed that its proprietary aerosol delivery system (ADS) delivered KL4 surfactant uniformly to all regions of the lung. The ADS is being developed… Read more . . .

Eurocine Vaccines has started a Phase 1/2 clinical study of its Immunose FLU intranasal quadrivalent influenza vaccine, which uses the company’s Endocine adjuvent and inactivated split antigens, the company said. Results should be available in… Read more . . .

Sunovion Pharmaceuticals and the American College of Chest Physicians (CHEST) have launched an initiative called “Delivery Makes a Difference,” which they say “seeks to understand patient and health care provider practices and to provide tools… Read more . . .

Theravance Biopharma and Mylan have announced that two 12-week Phase 3 efficacy studies of nebulized revefenacin (TD-4208) for the treatment of COPD have met their primary efficacy endpoint of statistically significant increase in FEV1 for… Read more . . .

Aradigm Corporation has partnered with Professors Daniela Traini and Paul Young of the University of Sydney’s Woolcock Institute of Medical Research to develop an aerosol nanoparticle technology to combat fungal and bacterial biofilms. The project… Read more . . .